119 related articles for article (PubMed ID: 38906916)
1. Temozolomide promotes matrix metalloproteinase 9 expression through p38 MAPK and JNK pathways in glioblastoma cells.
Thanh HD; Lee S; Nguyen TT; Huu TN; Ahn EJ; Cho SH; Kim MS; Moon KS; Jung C
Sci Rep; 2024 Jun; 14(1):14341. PubMed ID: 38906916
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
3. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
4. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
5. IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9.
Huang Q; Lan F; Wang X; Yu Y; Ouyang X; Zheng F; Han J; Lin Y; Xie Y; Xie F; Liu W; Yang X; Wang H; Dong L; Wang L; Tan J
Mol Cancer; 2014 Jan; 13():18. PubMed ID: 24479681
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y
J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087
[TBL] [Abstract][Full Text] [Related]
7. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
8. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
9. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
10. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway.
Peng Y; He X; Chen H; Duan H; Shao B; Yang F; Li H; Yang P; Zeng Y; Zheng J; Li Y; Hu J; Lin L; Teng L
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30061180
[TBL] [Abstract][Full Text] [Related]
12. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
13. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide does not influence the transcription or activity of matrix metalloproteinases 9 and 2 in glioma cell lines.
Suzuki Y; Fujioka K; Ikeda K; Murayama Y; Manome Y
J Clin Neurosci; 2017 Jul; 41():144-149. PubMed ID: 28408249
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Jin L; Kiang KM; Cheng SY; Leung GK
Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
17. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation.
Vo VA; Lee JW; Lee HJ; Chun W; Lim SY; Kim SS
Anticancer Res; 2014 Oct; 34(10):5509-15. PubMed ID: 25275048
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
20. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
